Understood, and I withdraw the assumption I opened with.
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Semaglutide half-life is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Confirming post #75 from a second method, which matters more than confirming it from a second person.
An honest declaration on Semaglutide half-life: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
This follows post #88 rather than contradicting it.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
This is the version I would want a new member to read first.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
The failure mode on Semaglutide half-life is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Read the full topic (133 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. Semaglutide and gastric emptying,…
|
+115 | 122 | 2.6k | 1d |
|
About the Semaglutide category
GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
|
4 | 4.2k | 11mo | |
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first…
|
2 | 39k | 6mo | |
|
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have spent a fortnight trying…
|
+72 | 77 | 7.2k | 19mo |
|
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…
|
+5 | 9 | 30k | 8d |
Related topics — sharing the tags STEP programme, type 2 diabetes, randomised trial
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Comparators chosen for regulatory reasons rather than clinical ones
On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. An honest uncertainty about comparators chosen for regulatory reasons…
|
2 | 27k | 14mo | |
|
Measurement error in home scales, with a worked standard deviation
Measurement error in home scales, with a worked standard deviation Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of measurement error…
|
+26 | 31 | 4.3k | 4mo |
|
Adjudicated events and why the definition matters — the long version
Adjudicated events and why the definition matters — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Adjudicated events, deliberately…
|
+125 | 146 | 13k | 15mo |
|
Journal club: FLOW and the renal composite, component by component
On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Reading FLOW ( N Engl J Med , 2024) for the population rather than the…
|
+84 | 91 | 18k | 2y |
|
An ABAB design with a data table and honest limitations — a second dataset
On the subject in the title: An ABAB design with a data table and honest limitations — a second dataset Working notes rather than a conclusion. Posting a small dataset on ABAB design. It is mine, it is…
|
+106 | 118 | 25k | 4mo |